Encorafenib is a kinase inhibitor used to treat unresectable or metastatic melanoma with BRAF mutations. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
- Mechanism
- Curator reviewed · 1 reference
Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36, and reduce ligand binding to these kinases at clinically achievable concentrations (≤0.9 µM).
- Primary indication
- Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF...Curator reviewed · 8 structured indications
- Formula / weight
- C22H27ClFN7O4S · 540.01 g/mol (avg)
- First approval
- Canada, 2021 · United States, 2018 · European Union, 2021
- Code names
- LGX-818 · NVP-LGX818 · NVP-LGX-818-NXA · ONO-7702 · PF-07263896 · W0090
- Brand names
Resolves to
CMJCXYNUCSMDBY-ZDUSSCGKSA-NSMILESCOC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Encorafenib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account